Phase 3 LATITUDE Atlas data presented at EADV 2026 showed higher rates of complete and near-complete skin clearance with zasocitinib compared with deucravacitinib.
Shannon Heaning, Content Associate
Advertisement
Shannon Heaning is a content associate for Dermatology Times® and joined the MJH Life Sciences team in June 2026. She graduated summa cum laude from Loyola University Maryland with a Bachelor of Arts in sociology and earned the top GPA in her major. Before joining Dermatology Times®, Shannon gained experience in clinical research, patient advocacy, and health communications. She is particularly passionate about rare disease awareness and patient-centered storytelling. Outside of work, she enjoys reading, drawing, and spending time with her dogs.
You can reach her at: sheaning@mjhlifesciences.com
Articles by Shannon Heaning, Content Associate
Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa.
Phase 2b SPOTLIGHT-204 results presented at EADV 2026 showed complete clinical and pathological responses in more than half of patients with high-risk head and neck basal cell carcinoma.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
New phase 2 data presented at EADV 2026 demonstrated significant improvements in disease activity with daxdilimab, with responses emerging as early as week 4.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.
Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
Stay ahead with a weekly roundup of the biggest practice management, AI, policy, business, and professional development updates in dermatology.
From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Dermatology Times and NPPA Connect celebrate National APP Week 2026 by highlighting the voices, experiences, and impact of advanced practice providers in dermatology.
Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.
Lauren Miller, PA-C, reflects on nearly 20 years in dermatology and how the PA profession has allowed her to grow as a clinician, educator, author, and mentor.
Donna Lam Cahill, PA-C, discusses her path to dermatology, patient advocacy, career persistence, and the evolving role of PAs during National APP Week.
Alexandra Charrow, MD, discussed biologic selection, deroofing, and emerging procedural approaches to hidradenitis suppurativa at Maui Derm NP+PA Fall 2026.
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Immunovant will discontinue development of imeroprubart in cutaneous lupus erythematosus after the phase 2b study failed to meet its primary endpoint.
This review of the latest dermatological studies includes insights on artificial intelligence, interstitial granulomatous dermatitis and atopic dermatitis
Jamie Nichole Restivo, MPAS, PA-C, reflects on her path to dermatology, the evolving role of APPs, and the power of collaboration during National APP Week.
For Alopecia Awareness Month, Deann of Alopecia Life discusses compassion, treatment expectations, and the psychosocial burden of alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Test your knowledge of the hidden costs, financial metrics, and operational decisions that can shape a dermatology practice.
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
Hidradenitis Suppurativa Claims Data: Sex Parity and Rural Care Gaps
2
Regenerative Approaches in Skin and Hair Care and Hair Loss Research
3
First-in-Class Oral PKM2 Modulator Shows Early Efficacy in Atopic Dermatitis
4
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
5